Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

University of Oxford

http://www.ox.ac.uk/

Latest From University of Oxford

Finance Watch: VC Fundraising Dips In Q2, But Mega-Deal Pace Is Strong

Private Company Edition: The amount of venture capital raised by biopharma firms fell but individual companies grabbed a lot of cash, making for a remarkable Q2 relative to pre-pandemic times. Recent Q3 rounds includes Frontera’s $160m series B. Also, Oxford Science Enterprises added €250m to its fund.

Financing Innovation

Dr Reddy’s Pressing On In Russia, China Approvals Add Spark

Momentum for Dr Reddy’s in China as a string of approvals including for lenalidomide come through, while it appears to be on an even keel in Russia, a market where several foreign firms have cutback activities in the wake of the Ukraine conflict. Will the Indian firm’s Russia strategy payback?

Strategy Sales & Earnings

Dr Reddy’s Pressing On In Russia, China Approvals Add Spark

Momentum for Dr Reddy’s in China as a string of approvals including for lenalidomide come through, while it appears to be on an even keel in Russia, a market where several foreign firms have cutback activities in the wake of the Ukraine conflict. Will the Indian firm’s Russia strategy payback?

Commercial India

Biocon Joins Fray For Denosumab, Ustekinumab Biosimilars

Biocon is progressing trials for biosimilar rivals to Amgen’s Prolia/Xgeva (denosumab) and J&J’s Stelara (ustekinumab), even as it gears for other large opportunities coming its way via the Viatris deal including for blockbusters Humira and Eylea.

Biosimilars Strategy
See All

Company Information

  • Industry
  • Academic and Research Institutions
  • Other Names / Subsidiaries
    • Oxford University Innovation
UsernamePublicRestriction

Register